Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.

Corradi M, Goldoni M, Alinovi R, Tiseo M, Ampollini L, Bonini S, Carbognani P, Casalini A, Mutti A.

Anticancer Res. 2013 Dec;33(12):5517-24.

PMID:
24324091
2.

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.

Jakubec P, Pelclova D, Smolkova P, Kolek V, Nakladalova M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):472-9. doi: 10.5507/bp.2014.015. Epub 2014 Apr 29.

3.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

4.

Sensitivity of urinary mesothelin in patients with malignant mesothelioma.

Creaney J, Musk AW, Robinson BW.

J Thorac Oncol. 2010 Sep;5(9):1461-6.

5.

Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.

Felten MK, Khatab K, Knoll L, Schettgen T, Müller-Berndorff H, Kraus T.

Int Arch Occup Environ Health. 2014 Feb;87(2):195-204. doi: 10.1007/s00420-013-0853-1. Epub 2013 Feb 20.

PMID:
23423281
6.

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.

J Thorac Oncol. 2008 Nov;3(11):1317-24. doi: 10.1097/JTO.0b013e318187491c.

7.

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.

Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.

Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.

8.

Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.

Weber DG, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B, Kollmeier J, Bauer TT, Brüning T.

PLoS One. 2014 Dec 3;9(12):e114483. doi: 10.1371/journal.pone.0114483. eCollection 2014.

9.

Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.

Lung. 2014 Feb;192(1):197-203. doi: 10.1007/s00408-013-9526-9. Epub 2013 Oct 30.

PMID:
24170217
10.

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46. doi: 10.1158/1055-9965.EPI-10-0346. Epub 2010 Jul 22.

11.

Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.

Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2014 Dec;34(12):7425-9.

PMID:
25503183
12.

Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.

Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A.

Lung. 2016 Jun;194(3):409-17. doi: 10.1007/s00408-016-9868-1. Epub 2016 Mar 31.

PMID:
27032653
13.

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.

Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.

J Thorac Oncol. 2008 Aug;3(8):851-7. doi: 10.1097/JTO.0b013e318180477b.

14.

Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.

Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T.

J Thorac Oncol. 2010 Apr;5(4):479-83. doi: 10.1097/JTO.0b013e3181d2f008.

15.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

16.

The place of YKL-40 in non-small cell lung cancer.

Kırankaya Güneş A, Gül Ş, Tutar N, Özgül MA, Çetinkaya E, Zengi O, Onaran H.

Tuberk Toraks. 2014;62(4):273-8.

17.

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.

Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW.

Chest. 2007 Oct;132(4):1239-46. Epub 2007 Jul 23.

PMID:
17646232
18.

Validity of mesothelin in occupational medicine practice.

Smolková P, Nakládalová M, Zapletalová J, Jakubec P, Vildová H, Kolek V, Petřek M, Nakládal Z.

Int J Occup Med Environ Health. 2016;29(3):395-404. doi: 10.13075/ijomeh.1896.00637.

19.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
20.

Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.

Santarelli L, Staffolani S, Strafella E, Nocchi L, Manzella N, Grossi P, Bracci M, Pignotti E, Alleva R, Borghi B, Pompili C, Sabbatini A, Rubini C, Zuccatosta L, Bichisecchi E, Valentino M, Horwood K, Comar M, Bovenzi M, Dong LF, Neuzil J, Amati M, Tomasetti M.

Lung Cancer. 2015 Dec;90(3):457-64. doi: 10.1016/j.lungcan.2015.09.021. Epub 2015 Sep 25.

PMID:
26431916

Supplemental Content

Support Center